Transmission of serum parvovirus-like virus by clotting-factor concentrates.
The serum parvovirus-like virus (SPLV) is a ubiquitous human virus that suppresses the growth of bone-marrow stem cells in vitro. Antibody to it (anti-SPLV) was found in 28 (97%) of 29 children and young adults with haemophilia treated with clotting-factor concentrates but in only 36% of those who had received multiple blood transfusions and in 20% of age-matched controls. The increased anti-SPLV prevalence in haemophiliacs was significant and was not due to passive acquisition of antibody. Haemophiliacs in a residential school showed seroconversion and rises in anti-SPLV titre following the introduction of concentrate treatment. 10 days after receiving his first dose of factor-VIII concentrate a patient had viraemia and then an anti-SPLV IgM response. These observations show that SPLV is often transmitted in clotting-factor concentrates but not in transfused blood. Whether this transmission has any harmful effect is uncertain.
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis; D001769:Blood / Q000382:microbiology*; D001771:Blood Banks / Q000592:standards; D002648:Child; D002675:Child, Preschool; D005164:Factor IX / Q000009:adverse effects*; D005169:Factor VIII / Q000009:adverse effects*; D006467:Hemophilia A / Q000628:therapy; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007223:Infant; D010321:Parvoviridae / Q000276:immunology; D065227:Transfusion Reaction; D014777:Virus Diseases / Q000635:transmission*
D000914:Antibodies, Viral; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D005169:Factor VIII; D005164:Factor IX